We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Bioscience Launches New Animal-Free Immunoassay Interference Blockers

By LabMedica International staff writers
Posted on 26 Jul 2023

Meridian Bioscience Inc. More...

(Cincinnati, OH, USA) is spotlighting its newly-introduced animal-free immunoassay interference blockers at this year's AACC conference. Immunoassay interference can lead to false positives and negatives, resulting in incorrect interpretation and faulty patient diagnosis. Interference primarily stems from Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA, detected in up to 25% of patients, combined with HA, constitute the major factors contributing to false positives in immunoassays. Including blockers in every immunoassay is essential to avoid such interference. Traditionally, animal-based interference blockers have been employed to enhance assay accuracy; however, these are prone to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages, as evidenced during the COVID-19 pandemic.

Meridian's Life Science division has unveiled two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, offering a potential solution to these issues. These innovative blockers are completely animal-free and provide comparable or superior performance than traditional animal-derived blockers. Meridian's new K-Block and Mouse-Free IgG overcome the obstacles associated with conventional animal-based blockers. These advanced blockers enhance assay specificity, reduce lot-to-lot variability, comply with sustainability considerations, and minimize contamination risks from animal-derived components. Preliminary testing in ELISA-based assays has revealed a strong performance of K-Block and Mouse-FREE IgG compared to other commercial animal-derived blockers.

The introduction of these products is in line with Meridian's objective to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers. By adopting these animal-free products, manufacturers can contribute to reducing their environmental footprint by optimizing energy and resource consumption and maintaining compliance with emerging regulatory standards. Meridian continues to champion environmental responsibility within the industry and is showcasing the two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, at AACC 2023.

“At Meridian, we are deeply committed to supporting our customers who are seeking non-animal-derived raw materials in diagnostic assays,” said Lourdes Weltzien, Ph.D., President - Life Science, Meridian Bioscience. “Our novel 100% animal-free blockers deliver on this commitment while avoiding the need to consume millions of mice each year in the process. This innovative method not only allows us to scale up quickly but also delivers results that are equivalent or even superior in quality. With this new product line, we reaffirm our dedication to environmental sustainability and social responsibility, ensuring a more ethical and responsible approach in our operations as well as our customers.”

Related Links:
Meridian Bioscience Inc. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Urine Analyzer
respons® UDS100
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.